Neuromuscular Blockade Clinical Trial
Official title:
Assessment of Residual Paralysis in Patients in the Postoperative Anaesthetic Care Unit (PACU)
The purpose of this study is to assess the incidence of residual block in patients arriving in the Post Anaesthetic Care Unit (PACU) following surgery, and in those who have received neuromuscular blocking drugs (muscle relaxants). Residual block (decreased motor function) due to residual levels of muscle relaxants is associated with increased morbidity.
This is a prospective, cross sectional study. Adult patients undergoing surgery in the main
operating theatres of Singapore General Hospital and requiring general anaesthesia and
muscle relaxants will be enrolled and assessed over a 4 month period.
Explanation, handing over of the Participation Information Sheet, and consent taking for the
research will be taken either: In the anaesthetic Pre-operative Evaluation Clinic (PEC)
which takes place on average 1-2 weeks prior to surgery itself; or On the ward, as a portion
of patients are admitted as an inpatient the day before surgery. This allows patients time
to consider participation into the study.
The conduct of anaesthesia before arrival in PACU is left to the discretion of the attending
anaesthetist. After arrival in PACU, patients are cared for by the PACU nurse and attending
anaesthetist. The PI or co-investigators of the participants will follow up patients
arriving in PACU if they fit the inclusion criteria i.e. who have received muscle relaxants
during their anaesthetic.
Participants will have their neuromuscular function monitored using a TOF Watch. This is a
neuromuscular monitor used to assess the twitch height of muscles when stimulated by small
electrical currents. Assessing neuromuscular function at all stages of anaesthesia (during
anaesthesia and during recovery from anaesthesia) is the standard of care and is considered
"essential" as per guidelines from the Association of Anaesthetists of Great Britain and
Ireland (2015).
The following are standards of care in PACU if patients are suspected of having residual
block:
1. Neuromuscular function will be assessed using clinical means (head lift and hand grip)
but these are unreliable (false positives due to effects of anaesthetic agents and
opioids rather than muscle relaxants)
2. Neuromuscular function assessed by either TOF count (number of twitches) or TOF ratio
(any fade in height of the four twitches) as per manufacturer's guidelines. Two ECG
electrodes will be placed 4 cm apart over the path of the ulnar nerve of the wrist
after cleaning the skin with alcohol swabs. The TOF force transducer will be placed on
the volar aspect of the thumb. The TOF Watch leads will be attached to the electrodes
and a TOF stimulus will be applied: four twitches at 2Hz (every 0.5 seconds), each
twitch lasting 0.2ms, and at a current of 50 milliamperes (mA).
3. Patients who have residual block will be closely monitored as per standard care in
PACU, which include oxygen therapy, and monitoring (continuous ECG, respiratory rate,
pulse oximetry, and 15 minutely non invasive blood pressure measurements). Those
patients who have clinical signs and symptoms of residual block will be treated at the
discretion of the PACU nurse and attending anaesthetic medical officer stationed in
PACU
For the research study in PACU, patients will have the above (steps 1 to 3) irrespective of
whether residual block is suspected.
In addition:
The TOF ratio will be measured as two sets of TOF ratio with an average of the two taken. As
far as possible, the TOF will be done when patients are still slightly drowsy from the
effects of anaesthesia in order to minimize any patient TOF discomfort. If there is >10%
discrepancy between these two readings then two more TOF will be applied, and an average of
the two closest measurement averaged. This will determine if the participant has residual
block (defined at TOF<0.9).
Medical record review of data will be that from intraoperative period and PACU stay (usually
one hour) and includes data already inputted into the anaesthetic charts:
1. Patient data: age, weight, BMI, American Society of Anaesthesiologists (ASA) status,
list of co-morbidities
2. Surgical data: type of operation and duration
3. Anaesthetic data: type, dose and timing of muscle relaxants and reversal used; type and
method of neuromuscular monitoring used
4. PACU data: time of arrival; heart rate, blood pressure, pulse oximetry and respiratory
rate on admission; any adverse incidents (airway obstruction, desaturation (SpO2<95%),
complaints of muscle weakness or blurred/double vision).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05558969 -
The Effect of Magnesium Use in Reversal of Neuromuscular Block With Sugammadex
|
N/A | |
Completed |
NCT03168308 -
Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients
|
Phase 4 | |
Not yet recruiting |
NCT03978780 -
Erector Spinae Block vs. Placebo Block Study
|
N/A | |
Completed |
NCT02912039 -
Electromyographic Assessment of the TetraGraph in Normal Volunteers
|
||
Completed |
NCT02892045 -
Mindray Neuromuscular Transmission Transducer
|
||
Completed |
NCT03427385 -
Minimum Local Anesthetic Dose for Adductor Canal Block
|
N/A | |
Completed |
NCT01450813 -
The Effect of Neuromuscular Blockade on the Composite Variability Index (CVI) During Laryngoscopy
|
N/A | |
Completed |
NCT00535496 -
Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)
|
Phase 3 | |
Recruiting |
NCT05794503 -
Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex
|
Early Phase 1 | |
Not yet recruiting |
NCT05993390 -
Pharmacological Reversal of Neuromuscular Blockade in Critically Ill Patients
|
N/A | |
Recruiting |
NCT04609410 -
Bleeding in Laparoscopic Liver Surgery
|
N/A | |
Terminated |
NCT03649672 -
The Validity and Tolerability of Awake Calibration of the TOF Watch SX Monitor
|
N/A | |
Completed |
NCT05474638 -
Comparison of Mechanomyographic 100 Versus 200 Hz 5 Second Tetanic Fade Ratios During Neuromuscular Block Recovery
|
N/A | |
Completed |
NCT05687253 -
Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery
|
Phase 2 | |
Completed |
NCT05120999 -
Comparison of Onset of Neuromuscular Blockade With Electromyographic and Acceleromyographic Monitoring
|
||
Completed |
NCT03572413 -
The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Innate Immune Homeostasis.
|
Phase 4 | |
Completed |
NCT03608436 -
The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Early Quality of Recovery
|
Phase 4 | |
Completed |
NCT02932254 -
Magnesium Sulfate Effect Following the Reversal of Neuromuscular Blockade Induced by Rocuronium With Sugammadex
|
Phase 4 | |
Completed |
NCT01828385 -
Effect of Magnesium on the Recovery Time of Neuromuscular Blockade With Sugammadex
|
Phase 4 | |
Completed |
NCT01809886 -
Reversal With Sugammadex From Deep Neuromuscular Blockade Induced by Rocuronium in Children: Randomised Clinical Trial
|
Phase 3 |